• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer.

作者信息

Agnelli Giancarlo

机构信息

From the Internal Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.

出版信息

N Engl J Med. 2019 Feb 21;380(8):781-783. doi: 10.1056/NEJMe1816060.

DOI:10.1056/NEJMe1816060
PMID:30786193
Abstract
摘要

相似文献

1
Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer.直接口服抗凝剂用于门诊癌症患者的血栓预防
N Engl J Med. 2019 Feb 21;380(8):781-783. doi: 10.1056/NEJMe1816060.
2
Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer.关于：利伐沙班用于癌症高危门诊患者的血栓预防
Eur Urol. 2020 Mar;77(3):388-390. doi: 10.1016/j.eururo.2019.10.019. Epub 2019 Nov 9.
3
[Thromboprophylaxis in patients with cancer].[癌症患者的血栓预防]
Internist (Berl). 2019 Sep;60(9):1004-1006. doi: 10.1007/s00108-019-0647-y.
4
Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm.直接口服抗凝剂用于癌症相关静脉血栓栓塞：是时候改变治疗模式了。
Cardiol J. 2020;27(4):347-349. doi: 10.5603/CJ.a2020.0067. Epub 2020 May 18.
5
Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.阿哌沙班预防接受化疗的高风险门诊癌症患者静脉血栓栓塞症：AVERT 试验的原理和设计。
Thromb Res. 2018 Apr;164 Suppl 1:S124-S129. doi: 10.1016/j.thromres.2018.01.018.
6
The best direct-acting oral anticoagulant for treatment of venous thromboembolism?用于治疗静脉血栓栓塞症的最佳直接口服抗凝剂是什么？
Lancet Haematol. 2019 Jan;6(1):e4-e5. doi: 10.1016/S2352-3026(18)30211-4. Epub 2018 Dec 14.
7
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.阿哌沙班在预防和治疗静脉血栓栓塞中的临床应用：当前证据
Drug Des Devel Ther. 2014 Nov 5;8:2181-91. doi: 10.2147/DDDT.S51006. eCollection 2014.
8
Anticoagulant Therapy for Venous Thromboembolism in Cancer.癌症患者静脉血栓栓塞的抗凝治疗
N Engl J Med. 2020 Apr 23;382(17):1650-1652. doi: 10.1056/NEJMe2004220. Epub 2020 Mar 29.
9
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.骨科手术后的新型口服抗凝药物用于血栓预防。
Best Pract Res Clin Haematol. 2013 Jun;26(2):171-82. doi: 10.1016/j.beha.2013.07.003. Epub 2013 Jul 26.
10
Apixaban or enoxaparin for thromboprophylaxis.阿哌沙班或依诺肝素用于血栓预防。
N Engl J Med. 2009 Nov 19;361(21):2100-1; author reply 2101. doi: 10.1056/NEJMc091817.

引用本文的文献

1
A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma.多发性骨髓瘤中直接口服抗凝剂用于血栓预防的系统评价
Res Pract Thromb Haemost. 2025 Apr 22;9(3):102865. doi: 10.1016/j.rpth.2025.102865. eCollection 2025 Mar.
2
Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China.中国直接口服抗凝剂与低分子量肝素及不进行血栓预防用于癌症相关静脉血栓栓塞一级预防的成本效益分析
Front Pharmacol. 2024 Sep 23;15:1373333. doi: 10.3389/fphar.2024.1373333. eCollection 2024.
3
Identification and validation of a novel 17 coagulation-related genes signature for predicting prognostic risk in colorectal cancer.
一种用于预测结直肠癌预后风险的新型17个凝血相关基因特征的鉴定与验证
Heliyon. 2024 Jun 7;10(12):e32687. doi: 10.1016/j.heliyon.2024.e32687. eCollection 2024 Jun 30.
4
Primary thromboprophylaxis in cancer outpatients - real-world evidence.癌症门诊患者的一级预防血栓栓塞症-真实世界证据。
J Thromb Thrombolysis. 2024 Jun;57(5):805-814. doi: 10.1007/s11239-024-02984-1. Epub 2024 Apr 20.
5
Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive.门诊癌症患者：哪些患者必须接受抗血栓预防治疗，哪些患者绝对不能接受。
Intern Emerg Med. 2023 Sep;18(6):1619-1634. doi: 10.1007/s11739-023-03306-8. Epub 2023 May 25.
6
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.一种用于预测癌症相关静脉血栓栓塞症的临床-遗传风险评分：涉及两个独立前瞻性队列的开发和验证研究。
J Clin Oncol. 2023 Jun 1;41(16):2911-2925. doi: 10.1200/JCO.22.00255. Epub 2023 Feb 2.
7
Prophylactic Anticoagulation in Patients with Cancer: When and How?癌症患者的预防性抗凝治疗：何时及如何进行？
Curr Oncol Rep. 2023 Mar;25(3):201-209. doi: 10.1007/s11912-023-01358-9. Epub 2023 Jan 27.
8
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.多发性骨髓瘤血栓并发症的当代风险评估、预防及管理方法
Cancers (Basel). 2022 Dec 16;14(24):6216. doi: 10.3390/cancers14246216.
9
Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients' and Clinicians' Awareness.癌症相关血栓形成（CAT）患者静脉血栓栓塞预防与治疗的多学科护理：教育干预对CAT相关事件以及患者和临床医生认知的影响
Life (Basel). 2022 Oct 13;12(10):1594. doi: 10.3390/life12101594.
10
Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment.静脉血栓栓塞症与癌症：从病理生理学到新型治疗的全面综述。
Biomolecules. 2022 Feb 4;12(2):259. doi: 10.3390/biom12020259.